Are durva/cis/gem or pembro/cis/gem less efficacious in cholangiocarcinomas with FGFR2 fusions?

And is there any role in utilizing FGFR2 inhibitors in first line setting?

The PROOF trial utilizing Infigratinib in first line was stopped after the company discontinued the development of the drug.

Answer from: Medical Oncologist at Academic Institution

I have not been able to find an answer to this question. The NCCN and French National Clinical Practice Guidelines both continue to recommend first line treatment with Gemcitabine/Cisplatin and Durvalumab. Exceptions include NTRK gene fusions and MSI-H/dMMR where NTRK inhibitors (e.g. entrectinib, l...

Comments

Medical Oncologist at OHSU
I agree, the one addition is that Gem/Cis/Pembro i...

Medical Oncologist
This reminds me of MSI-high colorectal patients pr...

Please select the option that best describes you:

Are durva/cis/gem or pembro/cis/gem less efficacious in cholangiocarcinomas with FGFR2 fusions?

Related Questions